| Oct 28 |
DOJ throws wrench into J&J bankruptcy plan to settle talc suits
|
| Oct 28 |
J&J’s $8.2 Billion Talc Settlement Faces January Court Test
|
| Oct 28 |
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
|
| Oct 28 |
J&J Impella ECP heart pump meets primary endpoint
|
| Oct 28 |
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
|
| Oct 28 |
JNJ's subcutaneous Tremfya demonstrates efficacy in Crohn's
|
| Oct 28 |
This Johnson & Johnson Insider Reduced Their Stake By 37%
|
| Oct 28 |
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
|
| Oct 26 |
3 Dividend Growth Stocks You Can Buy and Hold Forever
|
| Oct 25 |
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
|
